Mechanical Complications of IHD

부산의대 제형곤

Contents

- Ischemic MR (Chp. 92)
 - Carpentier's type IIIB dysfunction
 - Acute Papillary Muscle Rupture
 - Chronic Type II Ischemic Mitral Regurgitation
- Post-MI VSD & Ventricular Rupture (Chp. 93)
- Left Ventricular Aneurysm (Chp. 100)



Ischemic MR

부산의대 제형곤

Ischemic MR Definition

- Etiology: MI with regional or global dysfunction
- **<u>Primary lesion</u>**: tethering of the valve leaflets
- Valve dysfunction: MR restriction of leaflet

motion, in systole (Carpentier's type IIIB dysfunction)

Mitral valve anatomy



Functional classification of MR

- Type I : nl motion, leaflet perforation, annular dilatation
- Type II : chordae elongation or rupture
- Type IIIa : restricted motion(sys and dia) d/t rheumatic change
- Type IIIb : restricted motion(sys) secondary to PM displacement





Prevalence of IMR

- "Contaminated", usually mild & disappear
- 17%-55% develop mitral systolic murmur or

echocardiographic evidence of IMR early after AMI

• 18% cardiac catheterization within 6 hrs of the onset of

Sx of AMI

Degree of the of IMR

- Significant 2' mitral regurgitation:
 - Regurgitant volume \geq 30 mL
 - Effective regurgitant orifice area \geq 20 mm²
 - Flow-convergence proximal isovelocity surface area >

```
8 \sim 9, rather than > 10
```

TEE Assessment of IMR

- **Downgrading of MR** d/t unloading effect of anesthesia
- Provocative testing :
 - Preload challenge; PCWP 15~18 mmHg
 - Afterload challenge; mean AP > 100 mmHg
 - if positive, inspection & repair of MV

Byrne et al, Brigham & Women's Hospital, The Lancet '00

Clinical Presentation

- Acute MR d/t papillary muscle rupture after AMI
- Majority:
 - Prior MI, generally permanent and chronic
 - Incidental finding at echo
 - Symptoms and signs of heart failure

2 Most common clinical scenarios

Primarily Ischemia





Mechanism	Posterior leaflet restriction	Leaflet restriction and annular dilation
Severity of MR	Mild to moderate	Moderate to severe
LV dysfunction	Mild to moderate	Moderate to severe
Ejection fraction (%)	30-50	15-40
Indication for surgery	Coronary artery disease	Congestive heart failure

Pathophysiology of IMR



Pathophysiology of IMR

• LV sphericity is more important

than LV volumes or EF

• Inf. MI: tethering in medial

posterior leaflet

• Ant. MI: widespread tethering of both leaflets



Long term outcome



Figure 1. Survival (±SE) after diagnosis according to presence of IMR.

Worsens long term Px, increasing mortality - Grigioni, Circulation 2001

Survival after PCI



Preoperative Decision Making



Therapeutic Targets in IMR

- Coronary Artery Disease: CABG
- Mitral Annulus: Principal target
- Subvalvular Apparatus
- Leaflets
- Left Ventricle

CABG alone or CABG + MV



 "Treatment of Mitral valve should be considered if the degree is 2+ more ." Lam, Gillinov 2005 ATS

Annulus: Restrictive annuloplasty

- Complete rigid or semirigid rings are preferred
- Incomplete annuloplasty, flexible bands: not reduce the SL dimension



Subvalvular Apparatus; Chordae cutting



Surgical approach to "Tethering"; Cutting the secondary chordae to the AMVL Messas Circulation 2003











Baseline Normal Post-Infarct PM Displacement **Post-Infarct** Chordal Cutting

Subvalvular Apparatus; External devices



Hung J, Guerrero, et al, MGH, Circ '02



Subvalvular; PM reapproximation



Surgical approach to "Tethering "; APM & PPM reapproximation Matsui JTCS 2004

Subvalvular; PM Kron-repositioning



Subvalvular; Papillary Muscle Sling

- Hvass and Joudinaud, Paris.
- Goretex 4mm tube passed around both PM and approximated
- 37 pts since 2000
- 2 op deaths
- LVEDD 70 -> 56 at 1 yr
- EF 30-> 49



J Thorac Cardiovasc Surg 2010;139:418-23

Leaflets; Edge-to-edge





Figure 2. An atrial view of the MitraClip device (Abbott Vascular) grasping both leaflets of the mitral valve.

Leaflets; AMVL augmentation



AMVL augmentation (bovine pericardium) *Kincaid ATS 2004*

Leaflets; PMVL augmentation



Left Ventricle; Menicanti's



MVP with Intraventricular papillary muscle imbrication, Heart Fail Review 2004

Left Ventricle; Dor operation



Left Ventricle: Coapsys



Left Ventricle: Coapsys









Grossi, RESTOR-MV, JACC '2010

Chordal Sparing Replacement



Annuloplasty: preoperative LVEDD


STICH: 3-4+ IMR: Trend towards CABG alone worse than Med Rx, worse than CABG + MV Repair



MR > 2+ After Annuloplasty



Magne: Cardiology 2009;112:244–259

Possible Mechanisms of Residual MR

Length of the coaptation zone >8 mm



Ring type and Residual MR



- Surgical technique included restrictive annuloplasty in all patients.
- Surgical technique did not include restrictive annuloplasty in all patients.

Predictors of Recurrent MR after Annuloplasty for IMR

- TTE- Indicators of Severe Mitral Valve Tenting
 - Systolic tenting area $\geq 2.5 \text{ cm}^2$
 - Systolic tenting height \geq 10 mm
 - Posterior mitral leaflet angle ≥ 54 degrees
 - Distal anterior mitral leaflet angle \geq 19 degrees
 - Posterior mitral leaflet angle ≥ 45 degrees
 - Anterior mitral leaflet tethering angle \geq 39.5 degrees
 - MR jet direction: central or complex

Predictors of Recurrent MR after Annuloplasty for IMR

- TTE- Indicators of Advanced LV Remodeling
 - LVESD > 51 mm, LVEDD > 65 mm, LVESV \geq 145 mL
 - Interpapillary muscle distance > 20 mm
 - Systolic sphericity index \geq 0.7
- TTE other:
 - Myocardial performance index \geq 0.9
 - Wall motion score index \geq 1.5
 - Diastolic LV function: restrictive filling

Predictors of Recurrent MR after Annuloplasty for IMR

- TEE:
 - Mitral annular diameter in diastole > 3.7 cm
 - Tethering area > 1.6 cm2
 - MR severity > 3.5
- Surgical:
 - Use of flexible ring
 - Use of incomplete ring
 - Inadequate ring sizing
 - Length of leaflet coaptation < 8 mm</p>
 - Residual MR at OR or discharge
 - Absence of early LV remodeling (decrease of LVESV < 15%)

MVP for IMR: in Sabiston

- Severe IMR: should be corrected at CABG
 - MVR is a reasonable option
- Moderate IMR: No consensus but...
 - MVP should undergo unless prohibitive risk:
 - Extensive MAC
 - Strong indication for OPCAB: heavily diseased aorta
 - MVR: unclear efficacy and safety

Surgeons Prefer Repair



Years 2008-2012, The Adult Cardiac Surgery Database, The Society of Thoracic Surgeons

Left Ventricular Dysfunction

Impact of Mitral Valve Annuloplasty on Mortality Risk in Patients With Mitral Regurgitation and Left Ventricular Systolic Dysfunction

Audrey H. Wu, MD, MPH,* Keith D. Aaronson, MD, MS,* Steven F. Bolling, MD, FACC,† Francis D. Pagani, MD, PHD, FACC,† Kathy Welch, MS, MPH,‡ Todd M. Koelling, MD, FACC* *Ann Arbor, Michigan*



Cardiac Surgery

Impact of Mitral Valve Annuloplasty Combined With Revascularization in Patients With Functional Ischemic Mitral Regurgitation

Tomislav Mihaljevic, MD,* Buu-Khanh Lam, MD,* Jeevanantham Rajeswaran, MSc,† Masami Takagaki, MD,* Michael S. Lauer, MD,‡ A. Marc Gillinov, MD,* Eugene H. Blackstone, MD,*† Bruce W. Lytle, MD*

Cleveland, Ohio



Mihaljevic et al., JACC Vol. 49, No. 22, 2007



The NEW ENGLAND JOURNAL of MEDICINE 370:23-32. 2014

ORIGINAL ARTICLE

Mitral-Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation

Michael A. Acker, M.D., Michael K. Parides, Ph.D., Louis P. Perrault, M.D.,
Alan J. Moskowitz, M.D., Annetine C. Gelijns, Ph.D., Pierre Voisine, M.D.,
Peter K. Smith, M.D., Judy W. Hung, M.D., Eugene H. Blackstone, M.D.,
John D. Puskas, M.D., Michael Argenziano, M.D., James S. Gammie, M.D.,
Michael Mack, M.D., Deborah D. Ascheim, M.D., Emilia Bagiella, Ph.D.,
Ellen G. Moquete, R.N., T. Bruce Ferguson, M.D., Keith A. Horvath, M.D.,
Nancy L. Geller, Ph.D., Marissa A. Miller, D.V.M., Y. Joseph Woo, M.D.,
David A. D'Alessandro, M.D., Gorav Ailawadi, M.D., Francois Dagenais, M.D.,
Timothy J. Gardner, M.D., Patrick T. O'Gara, M.D., Robert E. Michler, M.D.,

ABSTRACT

BACKGROUND

Ischemic mitral regurgitation is associated with a substantial risk of death. Practice guidelines recommend surgery for patients with a severe form of this condition but

MVP vs. MVR for IMR

NEJM, Acker et al. 370:23-32. 2014

- 1st multicenter, randomized trial
- No difference in
 - Survival
 - LV remodeling
 - QoL at 12 months
- MVP: higher recurrent MR
 - at 12 mo. (32.6% vs. 2.3%)



Repair for Moderate Ischemic MR

- Longer CPB and ACC times
- More transfusions, Afib
- Greater LOS
- Perhaps: improved functional status
- Definitely: no survival benefit

Ischemic MR: Today's Options

- Residual regurgitation: poor long-term outcomes
- Severe ischemic MR
 - Repair: trend of survival benefit STICH -> only if simple: coaptation depth < 1.0
 cm, tenting area < 2.5 cm², LVEDD < 65mm, (anterior tethering angle < 26, posterior tethering angle < 45)
 - Replace: high risk pts. (STS PROM > 4, frail, aged)
- Moderate ischemic MR
 - Replacement: rarely needed
 - Repair: improve Sx. and LV, LA dilation but NO SURVIVAL BENEFIT of annuloplasty
 - CABG+MV repair < CABG alone</p>

Acute Papillary Muscle Rupture

- Historically, up to 5% of STEMI
- Reduced remarkably in the era of early reperfusion
- Post. PM: susceptible to ischemia d/t single vascular supply
- Ant. PM: dual supply from LAD and Diagonal br.
- About 1 week after AMI
- Sx: new systolic murmur, hemodynamic collapse, shock
- DDx: infarct VSD, LV free-wall rupture, global LV dysfunction

Acute Papillary Muscle Rupture

- Surgery should not be delayed
- MVR: most common Tx
- MVP with reimplantation of PM
- Hospital mortality: 20%



Chronic Type II IMR

• Chronic elongation, thinning, and

fibrosis or rupture of PM

- Fibrotic and thinned-out PM with normal chords
- Usually repairable
- PTFE-NCF, chordal transfer, PM-

transposition, downsized annuloplasty



Classification of papillary muscle rupture

Post-MI VSD & Ventricular Rupture 부산의대 제형곤

History of VSR



- Latham in 1845
 - First described at autopsy
- Cooley in 1956
 - First successful surgical repair in a patient after 9 weeks through RVtomy after VSR
- Heimbecker, Allen, Woodwark, Iben
 - Late 1960s: surgery for acute phase

Incidence and Demographics

- 1-2% of AMI and **0.2% in thrombolytic era**
- 5% of early deaths after MI
- Male : Female = 3 : 2
- 1 vessel (64%), 2 vessels (7%), 3 vessels (29%)
- Average age: 62 yrs (range, 44-81)
- Most often after the 1st AMI

Etiology and Pathogenesis



Etiology and Pathogenesis

- Post MI VSD:
 - Timing: usually 2 ~ 4 days
 - A few hours ~ 2 weeks
 - Closer to 1 day in thrombolytic era
 - Chronic VSR: more than 4 ~ 6 weeks
- LV free-wall rupture:
 - Occur 4%-8% of AMI
 - 15% of deaths after AMI
 - typically occurs 1-4 days after MI
 - Dx: echocardiogram

Pathophysiology



- Heart failure
 - Size of infarction
 - Amount of L-R shunt
- Anterior septal rupture
 - LV dysfunction
- Posterior septal rupture
 - RV dysfunction

Pathophysiology



Natural History

- Without surgical intervention:
 - 25% of pts: Died within first 24 hours
 - 50% of pts: Died within 1 week
 - 75% of pts: Died within 1 month
 - 7% of pts: Lived longer than 1 year

• Defer early op: deprives chance for successful op.

Clinical Presentation

- Harsh new holosystolic murmur: radiate to axilla
- recurrent chest pain
- RV failure and pulmonary edema is rare ??
- Resemble acute MR with PM rupture
 - VSD: Ant. AMI with condunction abnormality
 - IMR with PM rupture: post. AMI, no conduction abn'l



Diagnosis

- History of AMI
- Physical Examination and Monitoring
 - New systolic murmur
 - Abrupt deterioration in hemodynamics
- Imaging Studies
 - Echo: Gold standard
 - Coronary angiography
 - LV catheterization : Not recommended
 - 9% step-up in the O_2 saturation

Preoperative Management

- Dx: indication for operation
- Shock: surgical emergency
- Preop multisystem organ failure:
 - unlikely to survive
 - benefit from a mechanical bridge: IABP, VAD
- Intermediate status: within 12 to 24 hours
- Completely stable(<5%): semi-elective

Preoperative Management



- IABP
 - Cardiac output
 - Lt. to Rt. shunt
 - Coronary Perfusion
- Medications
 - Inotropics
 - Diuretics
 - Vasodilators (?)

Predictors of Risk

TABLE 93-1 Preoperative Predictors of Death after Surgical Repair of Postinfarction VSD

Variable	Predictor of Early Death	Predictor of Late Death
Need for preoperative catecholamines	<i>P</i> = 0.001	P=NS
Emergent operation	<i>P</i> < 0.0001	P = NS
Anterior VSD	<i>P</i> = 0.04	P = NS
Age > 65 years	<i>P</i> = 0.009	P = NS
Right-sided heart failure	<i>P</i> = 0.01	<i>P</i> = 0.005
Elevation in blood urea nitrogen	<i>P</i> = 0.02	P = NS
Elevation of serum creatinine	P = NS	<i>P</i> < 0.05
Previous myocardial infarction	P = NS	<i>P</i> < 0.05
Presence of left main coronary disease	P = NS	<i>P</i> < 0.05

Predictors of Risk

- Post. VSD increased operative mortality:
 - Technically difficult
 - Risk of mitral regurgitation is increased
 - RV failure with RV infarction
- Proximal VSDs strongly predict early mortality
 - Largest infarctions

Goal of Surgery

Exclusion or removal of infarcted myocardium

Elimination of Lt. to Rt. shunt

Resection of Infarcted Myocardium





Double Patch Repair of VSR





Balkanay et al. Tex Heart Inst J 2005;32:43-6
Surgical Techniques

Three Patch Technique







Infarct Exclusion Technique

Α VSD LV RV B VSD



Repair through Rt. Atrium





Massetti et al. (J Thorac Cardiovasc Surg 2000;119:784-9)

Closure of VSR on Beating Heart



Piotr Siondalski, Interactive CardioVascular and Thoracic Surgery 6 (2007) 160–162



Repair of Ant. PMI VSD



Repair of Post. PMI VSD







Weaning from CPB

- Bleeding
- Low cardiac output
 - IABP, Milrinone
- RV failure (especially posterior VSR)
 - Volume loading, Inotropics
 - PGE-1 (0.5 to 2.0 mg/min), NO gas (20 to 80 ppm)
- VAD, ECMO

Outcomes

- Operative mortality: 30% to 50%
- Most common cause of death
 - Low cardiac output: 52%
 - Technical failures(recurrent or residual VSD): 22%
 - Sepsis:17%, Recurrent infarction: 9%
 - CVA: 4%, Intractable ventricular arrhythmias

Long-Term Results

TABLE 93-2 Recent Clinical Experience* with Surgical Repair of Postinfarction V Septal Defect

Institution	City	Year	Patients (N)	Hospital Mortality (%)	5-year Survival (%)
Massachusetts General Hospital ¹	Boston	2002	114	37	45
University Hospital ⁶³	Zurich	2000	54	26	52 [†]
Glenfield General Hospital ²⁷	Leicester	2000	117	37 (30- day)	46
The Toronto Hospital ²⁴	Toronto	1998	52	19	65 [†]
Southhampton General ²⁰	Southampton	1998	179	27	49
MidAmerica Heart Institute ⁴⁶	Kansas City	1997	76	41	41
Green Lane Hospital ³¹	Auckland	1995	35	31 (30- day)	60 [†]
Hôpital Cardiologique du Haut-Lévèque ²⁸	Bordeaux	1991	62	38	44
CHU Henri Mondor ⁵³	Créteil	1991	66	45	44



FIGURE 93-4 🕑 Postdischarge survival rates after repair of postinfarction ventricular sept...

History of Free wall Rupture



- William Harvey
 - First described the free wall rupture

of the heart after AMI in 1647

- Hatcher, FitzGibbon, Montegut
 - First successful repairs in early 1970s

Incidence

- 11% of AMI (VSR x 10)
- Elderly women, first infarction, within 5 days
- Ant. > Lat.
- Simple versus complex (50:50)

Pathogenesis and Pathophysiology

- Transmural MI
- Infarct expansion
 - Acute regional thinning and dilatation of infarct zone
- Systemic HT, lack of collateral
- After extensive hemorrhagic transformation of AMI

Diagnosis

- Clinical picture of pericardial tamponade
- Echocardiography
 - Effusion thickness > 10mm
 - Echo-dense masses in the effusion
 - Ventricular wall defect

Natural History

- Acute
 - Death in a few minutes
- Subacute
 - Median survival : 8 Hours
 - Smaller tear, temporarily sealed by clot or fibrinous pericardial adhesions
- Chronic
 - False aneurysm

Surgical Technique

Epicardial patching



Debridement and patch closure



Direct suture



Infarct exclusion



Prêtre R, Ann Thorac Surg 2000;69:1342-5

Sutureless Tech.





Left Ventricular Aneurysm 부산의대 제형곤

Historical background

- 1957, Bailey: 1st successful surgical correction of an LV aneurysm
- 1958, Denton Cooley: open resection and simple closure on CPB
- 1968, Favaloro: 130 patients, resection for LV aneurysm, with 13% mortality

Natural course

- Recent 5YRS for medically managed LV dyskinesia : 47~70%
- Cause of death
 - Arrhythmia 44% : Heart failure 33%
 - Recurrent MI 11% : Non cardiac cause 22%
- Factors influencing survival of LV dyskinesia
 - Age : HF score : Coronary disease severity
 - Angina duration : Prior infarction : MR
 - Function of residual ventricle

Direct correlation between LV volume and survival

Relative Risk for Death Post MI



White HD. Circulation 1987

LVESVI greater than 60ml/m²: poor long term prognosis

Change LVESVI / survival*



Senior, AJC, 2001

Left Ventricular Remodeling

Box 100-1 Left Ventricular Remodeling

Myocardial Changes

- Myocyte loss
- Necrosis
- Apoptosis

Alterations in Extracellular Matrix

- Matrix degradation
- Replacement fibrosis

Alterations in LV Chamber Geometry

- LV dilation
- Increased LV sphericity
- LV wall thinning
- Mitral valve insufficiency

LV, Left ventricular.

Diagnostic modality

- Echocardiography
 - Screening method for detecting LV aneurysm
 - Useful for assessing MV function
- Cardiac MRI





Geometric measures



- Sphericity index (SI): shortto long-axis ratio (S/L)
- Conicity index (CI): apical to short-axis ratio (Ap/S)
- Apical diameter: best fits the apex
- SI has the same value in normal subjects and in patients with DCM
- Because the elongation of LV is proportional to the increase in width
- Whereas the CI is markedly abnormal in the patients.

Shape of LV

 Apex: enlarged(less conical) and shifted downward and toward the mitral plane in both systole (inner line) and diastole (outer line)



Silhouettes of LV shape abnormalities

Angiographic LV silhouettes-RAO 30



SVR for ICMP

• Dor, 1984: LV reconstruction

– If needed, CABG \pm MVP or MVR

- Technique: not standardized, many variations
 - Jatene: linear closure
 - Mickleborough: modified linear closure
 - Dor and Menicanti: circular closure with patch
 - McCarthy: double cerclage closure without patch

Linear closure by Jatene



Mickleborough procedure



Circular patch plasty



Endoventricular patch plasty



Surgical Ventricular Restoration



Surgical pitfalls during SVR

Box 100-3 Surgical Pitfalls

- Incorrect indications
- Incomplete revascularization
- Embolism
- Cavity dimension: too large or too small
- Cavity shape: spherical or distorted

Surgical Details of Anterior SVR

- Menicanti, 2001: RESTORE Group
 - If needed, CABG ± MVP 26mm sizer
- Mannequin:
 - 50 to 60 mL/m 2
 - New apex = apex of the Mannequin
 - Start 2/0 endoventricular circular suture
 - Reduces risk: too small residual cavity
 - Rebuilding of LV: in elliptical way
- If closure plane is parallel to MV: spherical LV

Surgical Ventricular Restoration

Use of intraventricular mannequin during SVR



B-C = plicated inferior fibrotic wall

B-C = segment fibrotic aneurysmatic wall

FIGURE 100-11 The use of the intraventricular mannequin during surgical left ventricle reconstruction

Suboptimal endoventricular suture



A, Suturing is done on a plane parallel to the mitral valve. B, The suture is tightened. C, The patch is inserted, and its resultant position is parallel to the mitral valve
Suboptimal endoventricular suture

Note the spherical left ventricular chamber achieved after surgery



Post-SVR

Pre-op

Surgical Ventricular Restoration



Outcomes and Prognosis

- Low early mortality
 - 2-13%
- Acceptable 5 and 10 year mortality
 - 5 year survival 58-80%
 - 10 year survival 30% (better than medical Tx)
- Most patients experience increased LV performance
 - LVEF ↑ PHTn↓ LV volume↓ MV O₂ demand ↓
 Exercise tolerance ↑

The STICH trial

(Surgical Treatment for Ischemic Heart Failure)

- Target registry 2800 patients with 90 participating centers
- Objectives to seek best treatment for coronary disease and heart failure (Inclusive of SVR)
- Groups
 - Medical therapy alone
 - Medical therapy & CABG
 - Medical therapy & CABG and SVR

STICH SVR Trial Design



Follow-up 99% complete at 48-months ~ 50% Mild Angina/~ 41% CCS III ~ 50% Class I/II NYHA/~ 43% Class III Range for ESVI was 23 – 284 ml/m²

Kaplan-Meier Estimates of the Rate of Hypothesis 2 Primary Endpoints of Death or Cardiac Hospitalization



Insights into the STICH Trial

- CABG alone or CABG +SVR-Hypothesis 2
- SVR + CABG: no impact over CABG alone
 - Mortality
 - Heart failure hospitalizations
 - Exercise tolerance
 - Quality of life

limitations of the STICH trial

- (1) Pt. inclusion bias: not randomized,
- (2) Smaller reduction of ESV
 - Questions: performed properly in a majority?
- SVR Goal: LVESVI < 60 mL/m^2
- ESC & EACTS: COR IIb, LOE B
 - Scar in the LAD territory
 - Baseline LVESVI \geq 60 mL/m²

Summary of SVR

- Choice to add SVR to CABG should be based on
 - heart failure symptoms
 - LV volumes
 - mitral valve: geometry and MR severity
 - transmural extent of myocardial scar tissue and viability
 - surgical expertise
- Appropriate patient selection criteria:
 - (1) ventricular properties better hemodynamic effects
 - (2) hemodynamic clinical outcomes